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Abstract
Background: Chagas disease is a major health problem in Latin America, and an emerging infectious disease in the US.
Previously, we have screened the Trypanosoma cruzi sequence database by a computational/bioinformatics approach, and
identified antigens that exhibited the characteristics of vaccine candidates.
Methodology: We investigated the protective efficacy of a multi-component DNA-prime/protein-boost vaccine (TcVac2)
constituted of the selected candidates and cytokine (IL-12 and GM-CSF) expression plasmids in a murine model. C57BL/6
mice were immunized with antigen-encoding plasmids plus cytokine adjuvants, followed by recombinant proteins; and
two-weeks later, challenged with T. cruzi trypomastigotes. ELISA and flow cytometry were employed to measure humoral
(antibody isotypes) and cellular (lymphocyte proliferation, CD4
+ and CD8
+ T cell phenotype and cytokines) responses.
Myocardial pathology was evaluated by H&E and Masson’s trichrome staining.
Principal Findings: TcVac2 induced a strong antigen-specific antibody response (IgG2b.IgG1) and a moderate level of
lymphocyte proliferation in mice. Upon challenge infection, TcVac2-vaccinated mice expanded the IgG2b/IgG1 antibodies
and elicited a substantial CD8
+ T cell response associated with type 1 cytokines (IFN-c and TNF-a) that resulted in control of
acute parasite burden. During chronic phase, antibody response persisted, splenic activation of CD8
+ T cells and IFN-c/TNF-
a cytokines subsided, and IL-4/IL-10 cytokines became dominant in vaccinated mice. The tissue parasitism, inflammation,
and fibrosis in heart and skeletal muscle of TcVac2-vaccinated chronic mice were undetectable by histological techniques. In
comparison, mice injected with vector or cytokines only responded to T. cruzi by elicitation of a mixed (type 1/type 2)
antibody, T cell and cytokine response, and exhibited persistent parasite burden and immunopathology in the myocardium.
Conclusion: TcVac2-induced activation of type 1 antibody and lymphocyte responses provided resistance to acute T. cruzi
infection, and consequently, prevented the evolution of chronic immunopathology associated with parasite persistence in
chagasic hearts.
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Introduction
Trypanosoma cruzi, a parasitic protozoan, is the etiologic agent of
Chagas disease. Chagas disease is the most common cause of
congestive heart failure related deaths among young adults in the
endemic areas of South and Central America and Mexico [1]. It
has also become an important health issue in the United States
and Europe due to large scale migration of Latin Americans over
the last few decades [2]. No vaccines are currently available.
Several investigators have documented that protective immune
mechanisms against T. cruzi are constituted of a strong lytic
antibody response, cytotoxic T lymphocytes activity, and Th1
cytokines [3–7] Towards identifying the potential vaccine
candidates, T. cruzi transfectants expressing ovalbumin (OVA,
model antigen) in different cellular compartments were developed.
Immunological studies in mice infected with OVA-transfectants
suggested that parasite GPI-anchored (released by default in host
cell cytoplasm) and secreted proteins were capable of entering the
class I and class II pathways of antigen presentation and eliciting
antibody and T cell responses, and, thus, would be the best choice
as vaccine candidates [8]. Accordingly, several GPI-anchored
proteins of T. cruzi have been identified, and their immunogenic
potential examined in mice. Many of the selected antigenic targets
provided variable degree of resistance to T. cruzi as DNA or
protein vaccine [5,9–13] (reviewed in [14–16]).
In parallel with the efforts towards identification of vaccine [9]
candidates, the development of methods to enhance the protective
efficacy of subunit vaccines against T. cruzi has been the primary
focus of research for several years. These include the use of
adjuvants, e.g. saponin with GP90 [17], alum with GP82 [9], IL-
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GMCSF in numerous studies (reviewed in [20]). Others have used
attenuated strain of Salmonella [21] adenovirus [22,23] for
antigen delivery, or a heterologous prime-boost protocols [24,25]
to enhance the selected candidates efficacy against T. cruzi.
We have employed an unbiased computational/bioinformatics
approach for screening the T. cruzi sequence database and
identification of potential vaccine candidates [26]. A strategic
analysis of the sequence database led to selection of 71 candidates
that were unique to T. cruzi, but not the members of the trans-
sialidase, mucin or other large gene families, and exhibited
multiple motifs/characteristics of secreted or GPI-anchored
proteins. Of these, eight candidates (TcG1, TcG2, TcG3, TcG4,
TcG5, TcG6, TcG7, and TcG8 [TcG1-TcG8]) were phylogenet-
ically conserved in clinically important strains of T. cruzi, expressed
in the infective and intracellular stages of the parasite [26], and
elicited varying level of lytic antibody response and Th1 cytokines
(IFN-c), a property associated with immune control of T. cruzi, in
immunized mice. TcG1-, TcG2-, and TcG4-encoded antigens
were expressed on the plasma membrane of the mammalian stages
of T. cruzi (trypomastigote/amastigote) and elicited significant
levels of anti-parasite lytic antibody responses in mice [26]. These
novel vaccine candidates, thus, increased the pool of protective
vaccine [17] candidates against T. cruzi.
Heterologous DNA-prime and protein-boost is a promising
vaccination approach. Delivery of antigens as DNA vaccine elicits
robust T cell response that can be further enhanced and
modulated to type 1 by co-delivery of IL-12 and GMCSF cytokine
adjuvants [27,28]. DNA immunization is also effective in priming
antigen-specific memory B cells. Delivery of vaccine candidates as
recombinant proteins is generally more effective at eliciting
antibody responses and may directly stimulate antigen-specific
memory B cells to differentiate into antibody-secreting cells,
resulting in production of high titer antigen-specific antibodies
[29,30]. Therefore, DNA-prime plus protein-boost is a comple-
mentary approach that overcomes the immunological limitations
of DNA/DNA and protein/protein vaccines, and DNA/protein
vaccines have been shown to elicit stronger, long-term cellular
immunity against intracellular pathogens [31,32].
In this study, we tested the protective efficacy of a DNA-prime/
protein-boost subunit vaccine (TcVac2) constituted of candidate
antigens that were identified by the computational/bioinformatic
analysis of T. cruzi sequence database. We discuss the TcVac2
efficacy in gearing the antibody, T cell and cytokine responses that
provided protection from acute parasitemia, and chronic parasite
persistence and immunopathology in chagasic mice.
Methods
Parasites and mice
Trypomastigotes of T. cruzi (Sylvio X10/4 strain) were
maintained and propagated by continuous in vitro passage in
C2C12 cells. C57BL/6 female mice (6-to-8 weeks old) were
obtained from Harlan Labs (Indianapolis, IN). Animal experi-
ments were performed according to the National Institutes of
Health Guide for Care and Use of Experimental Animals and
approved by the UTMB Animal Care and Use Committee.
T. cruzi genes, plasmid construction, and recombinant
proteins
Sequences for TcG1, TcG2 and TcG4 have previously been
submitted to Genbank (AY727914, AY727915, and AY727917,
respectively). TcG1 is 76% identical to the Leishmania donovani 23-
kDa cell surface protein [33]. TcG2 and TcG4 have been
identified in CL Brenner sequence database, and exhibit 99–100%
homology to XM_806323 and XM_816508, respectively [34].
The cDNAs for TcG1, TcG2, and TcG4 were cloned in
eukaryotic expression plasmid pCDNA3.1 [26] for DNA vaccina-
tion purposes. The eukaryotic expression plasmids encoding
murine IL-12 (pcDNA3.msp35 and pcDNA3.msp40) and GM-
CSF (pCMVI.GM-CSF) cytokines have been previously described
[5]. Recombinant plasmids were transformed into E. coli DH5-
alpha competent cells, grown in L-broth containing 100 mg/ml
ampicillin, and purified by anion exchange chromatography using
the Endo free maxi prep kit (Qiagen, Valencia, CA), according to
the manufacturer’s specifications.
For protein vaccination, cDNAs for TcG1, TcG2, and TcG4 were
cloned in pET-22b plasmid (Novagen, Gibbstown, NJ) such that
the encoded proteins were in-frame with a C-terminal His5-tag.
For the purification of recombinant proteins, plasmids were
transformed in BL21 (DE3) pLysS competent cells (Invitrogen,
Carlsbad CA) and recombinant proteins purified using the poly-
histidine fusion peptide-metal chelation chromatography system
(Novagen). After purification, proteins were exchanged out of
elution buffer by dialysis, and we validated that LPS contamina-
tion in the proteins was ,1.0 EU/ml determined by toxin sensor
limulus amebocyte lysate (LAL) assay kit (Genscript, USA Inc.). All
cloned sequences were confirmed by restriction digestion and
sequencing at the Recombinant DNA Core Facility at UTMB.
Immunization and challenge infection
C57BL/6 mice were injected in the quadriceps muscle twice at
three-week intervals with antigen-encoding plasmids
(pCDNA3.TcG1, pCDNA3.TcG2 and pCDNA3.TcG4, 25 mg
each plasmid DNA/mouse) and cytokine-encoding plasmids
(pcDNA3.msp35, pcDNA3.msp40 (IL-12) and pCMVI.GM-
CSF, 25 mg each plasmid DNA/mouse). Mice were then
immunized with two doses of TcG1-, TcG2-, and TcG4-
recombinant proteins (25 mg each, total 75 mg protein emulsified
in 5 mg saponin/100 ml PBS/mouse, intra-dermal). Two weeks
after the last immunization, mice were challenged with T. cruzi
(10,000 trypomastigotes/mouse, i.p.). Mice were sacrificed at day
30 and 120 post-infection (pi) corresponding to the acute phase of
peak parasitemia and the chronic phase of disease development,
Author Summary
Trypanosoma cruzi, a parasitic protozoan, is the etiologic
agent of Chagas disease. Chagas disease is the most
common cause of congestive heart failure related deaths
among young adults in the endemic areas of South and
Central America and Mexico. Vaccine development against
Chagas disease has been dramatically limited because of
extensive debate on the mechanisms involved in this
pathology. It is now accepted that the presence of
parasites in cardiac tissue is necessary to initiate and
maintain the inflammatory responses and that therapeutic
treatments or vaccines aimed at eliminating T. cruzi would
limit or prevent the progression of chronic chagasic
cardiomyopathy. In the present study, we have tested
the protective efficacy of a multi-component heterologous
DNA-prime/protein-boost vaccine TcVac2 in a murine
model of T. cruzi infection. Immunization of mice with
TcVac2 induced potent antibody, CD8
+ T cell and cytokine
responses that provided protection from acute parasitemia
and chronic parasite persistence and immunopathology in
chagasic mice in comparison to unvaccinated mice.
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were harvested, and stored at 4uC and 280uC, respectively.
Antibody response
Sera samples were analyzed for IgG antibody levels by use of an
Enzyme Linked Immunosorbent Assay (ELISA) [13]. T. cruzi
lysate (5610
5 parasites equivalent/well) or recombinant antigens
(20 mg/ml) were used to capture the T. cruzi- and antigen-specific
antibodies, respectively. To identify the antibody sub-types, plates
were coated with T. cruzi antigen, and, then sequentially incubated
at room temperature with sera samples (1:50–1:1000 dilution,
100 ml/well) for 2 h, biotin-conjugated goat anti-mouse Ig
subtypes (IgG1, IgG2a, or IgG2b) for 30 min, and streptavidin-
horseradish peroxidase conjugate for 30 min. All antibodies and
conjugates were from Southern Biotech, and used at a 1:5000
dilution in PBST-0.5% NFDM (100-ml/well). Color was developed
with 100-ml/well Sure Blue TMB substrate (Kirkegaard & Perry
Labs, Gaithersburg, MD), reaction was stopped with 2N sulfuric
acid, and antibody response was monitored at 450 nm using a
SpectraMax M5 microplate reader. End point titers were defined
as the highest serum dilution that resulted in an O.D. value greater
than that of the mean plus two standard deviations of control
mouse serum.
Lymphocyte proliferation and cytokine levels
T. cruzi trypomastigote lysate (TcTL) was prepared by
subjecting parasites (10
9/ml PBS) to six cycles of repeated freezing
and thawing followed by sonication in an ice-cold water bath for
30 min. Single-cell splenocyte preparation from immunized and
control mice was suspended in RPMI-5% FBS. Cells were
adjusted to a concentration of 5610
5 cells/ml and were cultured
in 24- or 96-well plates for 48–72 h with added recombinant
proteins (10-mg/ml), T. cruzi lysate (25-mg/ml) or concanavalin A
(Con A, 5 mg/ml). Culture supernatants were collected at 48 h for
the measurement of IFN-c, TNF-a, IL-4 and IL-10 cytokines
using optEIA
tm ELISA kits (Pharmingen, San Diego, CA),
according to the manufacturer’s specifications. The cell suspension
in 96-well plates was stimulated for up to 72 h and utilized to
measure the rate of lymphocyte proliferation by MTT assay [35].
In this assay, the yellow tetrazolium salt (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) is reduced by mitochondrial
dehydrogenases in metabolically active live cells to insoluble
purple formazan crystals that are solubilized and quantitated at
540 nm by spectrophotometry.
Splenic level of CD4
+ and CD8
+ cell population in immunized/
challenged mice was determined by flow cytometry. Briefly,
splenocytes were suspended in PBS (1610
6 cells/100 ml) and
incubated for 30 min with FITC-conjugated anti-CD8 and PE-
conjugated anti-CD4 antibodies (1:50 dilution) (e-Biosciences,
CA). Following incubation, cells were fixed with 2% paraformal-
dehyde, washed and re-suspended in 500 ml PBS, and analyzed on
a FACScan apparatus (BD Biosciences). Cells stained with PE- and
FITC- conjugated rat IgGs (isotype matched) were used as
negative controls. Flow data were analyzed by Cell Quest software
(BD Biosciences).
Tissue parasite burden and histopathology
Skeletal muscle, heart spleen, liver and kidney tissues (50 mg)
were subjected to Proteinase K lysis, and total DNA was purified
by phenol/chloroform extraction and ethanol precipitation
method. Total DNA (100 ng) isolated from heart and skeletal
muscle was used as a template in a PCR reaction for 28 cycles with
oligonucleotides specific for T. cruzi 18S ribosomal DNA sequence
(Forward: 59-TAGTCATATGCTTGTTTC-39, Reverse: 59-
GCAACAGCATTAATATACGC-39) [36]. For validation of
PCR results, parasite burden in all tissues was monitored by
real-time PCR on an iCycler thermal cycler (Bio-Rad) with SYBR
Green Supermix (Bio-Rad) and Tc18S-sepecific oligonucleotides.
The real-time PCR amplification of Tc18SrDNA was calculated
using the formula fold change =2
2DCt, where DCt represents the
Ct (infected sample) - Ct (control) [37]. All data were normalized
with host-specific GAPDH.
For histological studies, skeletal muscle and heart tissues were
fixed in 10% buffered formalin for 24 h, dehydrated in absolute
ethanol, cleared in xylene, and embedded in paraffin. Five-micron
tissue sections were stained with hematoxylin and eosin or
Masson’s Trichrome, and evaluated by light microscopy. Tissues
were examined for evidence of cellular inflammation and fibrosis
and each section was assigned a histological score. The presence of
inflammatory cells was scored as (0) - absent/none, (1) - focal or
mild myocarditis with #1 foci, (2) - moderate with $2
inflammatory foci, (3) - extensive with generalized coalescing of
inflammatory foci or disseminated inflammation with minimal
necrosis and retention of tissue integrity, and (4) - severe with
diffused inflammation, interstitial edema, and loss of tissue
integrity. The foci of fibrosis and pseudocysts (parasite nests) were
scored as (0) absent, (1) 0–1 foci, (2) 1–5 foci, and (3).5 foci.
Statistical analysis
Data are expressed as means 6 SD, and derived from at least
triplicate observations per sample (n$8 animals/group). Results
were analyzed for significant differences using ANOVA proce-
dures and Student’s t-tests. The level of significance was calculated
vector only-versus-immunized and cytokine adjuvants only-versus-
vaccinated with TcVac2, and presented as
#p,0.05,
##p,0.01,
###p,0.001.
Results
Sera samples were collected after each immunization, and we
determined the development of TcVac2-induced antibody response
by an ELISA. Titration curves with sera after 4
th immunization
indicated that sera dilution at 1:100 provides the highest signal-to-
noise ratio and ability to detect antibody response in linear range
(Fig. 1A). All experiments were, therefore, conducted using sera
dilution of 1:100. Our data showed the sera level of T. cruzi-specific
antibodies were detectable after the second immunization, and
increased following each booster immunization with recom-
binant proteins (Fig. 1B). Antigen-specificity of antibody response,
determined in sera collected after last immunization, is shown in
Fig. 1C–E. We detected a substantial level of TcTL- and TcG1-,
TcG2- and TcG4-specific IgG (Fig. 1C), IgG2b (Fig. 1D), and
IgG1 (Fig. 1E) antibodies in mice immunized with TcVac2 (all,
p,0.0120.001).Thelevel ofantigen-specific antibodyresponsewas
detected in the order of TcG4.TcG2.TcG1; and the antigen-
specific antibody response was predominantly of the Th1 type with
IgG2b/IgG1 ratio.1 (Fig. 1D–E). Control mice immunized with
plasmid vector alone or cytokine adjuvants only exhibited no
parasite-(TcTL) and antigen-specific (TcG1, TcG2 TcG4) antibody
response (Fig. 1C–E).
To determine if vaccination elicited cellular responses, spleen
cells were collected two-weeks after last immunization, in vitro
stimulated with TcTL or recombinant proteins, and lymphocytes’
proliferation and cytokine secretion assessed. Mice vaccinated with
TcVac2 exhibited up to 25% increase in TcTL- and antigen-
specific(TcG4=TcG2.TcG1)lymphocytes’proliferation(Fig. 1F,
p,0.0520.001). Mice injected with cytokine adjuvants or vector
only exhibited minimal to no TcTL- and antigen-specific
TcVac2 Vaccine against T. cruzi
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TNF-a and IL-10) were below detection limit in supernatants
collected after 48 h in vitro stimulation of splenocytes from
vaccinated and non-vaccinated mice. Incubation with Con A
resulted in a substantial increase in IFN-c, TNF-a and IL-10
levels in splenocytes from all animal groups (range:
800±65.822500±215 pg/ml). Together, these results demon-
strated that TcVac2 induced TcTL- and antigen-specific Th1
antibodies, and lymphocytes’ proliferation in immunized mice.
To determine if vaccination with TcVac2 primed an improved
immune response to challenge infection, mice were infected with
T. cruzi and antibody response, lymphocytes’ proliferation and
cytokine levels monitored at the acute (30 dpi) and chronic (120
dpi) stages of infection and disease development. Shown in Figure 2
are antibody levels in vaccinated/challenged mice (sera dilution,
1:1000), determined by an ELISA. Vaccinated mice exhibited a
rapid increase in antibody response upon challenge infection as
was evidenced by ,2–3-fold higher levels of parasite- and antigen-
specific IgGs in vaccinated/acutely-infected mice as compared to
non-vaccinated/infected mice (Fig. 2A, p,0.0520.001). The
higher levels of TcTL- and antigen-specific antibody response in
vaccinated mice were maintained during the chronic phase
(Fig. 2B, p,0.0520.001). Similarly, sera level of IgG2b/IgG1
antibodies in TcVac2-vaccinated mice were higher than that
noted in unvaccinated mice at all stages of infection and disease
development (Fig. 2C–2F, p,0.0520.001). The level of antigen-
specific IgG and IgG2b antibodies in TcVac2-vaccinated/
challenged mice was in the order of TcG4.TcG2.TcG1. Mice
vaccinated with cytokine adjuvants exhibited slightly higher levels
of parasite- and TcG4-specific antibody response than the controls
given vector only, thus, indicating that cytokines alone moderately
enhanced the antibody response upon challenge infection (Fig. 2).
No significant difference was detected in the level of parasite-
induced IgG2a in vaccinated and non-vaccinated mice, and in
mice given cytokine adjuvants only (data not shown). Together,
these data showed that TcVac2 vaccination of mice resulted in a
rapid expansion of antibody response against challenge T. cruzi
infection, and this antibody response was maintained at least up to
day 120 pi when animals were sacrificed.
Splenocytes harvested at day 30 and 120 pi were in vitro
stimulated with TcTL or recombinant antigens, and we measured
the lymphocyte proliferation by MTT assay and cytokine levels by
ELISA (Fig. 3). All mice, irrespective of vaccination regimen,
responded to acute infection by a strong increase in parasite-
specific lymphocyte proliferation (Fig. 3A), and IFN-c (Fig. 3B)
and TNF-a (Fig. 3C) production (note the brick-bars with Tc-
lysate stimulation). However, a potent increase in antigen-specific
lymphocyte proliferation, and IFN-c and TNF-a production
(TcG4.TcG2.TcG1) was primarily observed in vaccinated/
infected mice (Fig. 3A–C, p,.05-p,0.001). Further, vaccinated/
acutely-infected mice mounted a type 1 biased cytokine response
as was evidenced by undetectable levels of IL-4 (Fig. 3D) and IL-
10 (Fig. 3E) cytokines in supernatants of splenocytes stimulated
with TcTL or specific antigens. In comparison, mice injected with
vector or cytokines only exhibited a mixed response and mounted
TcTL-dependent production of IL-4 (165±11.6 and
220±18.2 pg/ml, respectively) and IL-10 (350±25.9 and
465±45.5 pg/ml, respectively) cytokines (Fig. 3D&E). The mean
Figure 1. TcVac2 induced antigen-specific antibody response
and lymphocyte proliferation in immunized mice. C57BL/6 mice
were immunized with TcVac2 as detailed in Materials and Methods and
sera samples were collected after each immunization. (A) Sera samples
after last immunization were used to generate titration curves for T.
cruzi (TcTL) and antigen-specific (TcG1, TcG2, TcG4) antibody detection
in TcVac2-vaccinated mice. (B) T. cruzi specific IgG antibodies (sera
dilution, 1:100) were exponentially increased after each dose of
immunization in vaccinated mice. (C–E) Sera levels of parasite- and
antigen-specific IgG (C), IgG2b (D) and IgG1 (E) antibodies, measured
two-weeks after the last immunization. Sera levels of antibody isotypes
in normal mice (NM), and mice injected with vector alone or cytokine
(Cyt) adjuvants only are also shown. (F) Spleen cells were obtained 2-
weeks after last immunization and in vitro stimulated for 48 h with T.
cruzi trypomastigotes lysate (TcTL) or recombinant antigens (TcG1,
TcG2 and TcG4). Shown are the extent of lymphocytes proliferation in
TcVac2-vaccinated mice and mice given cytokines only (data normal-
ized to control mice given vector alone), measured by an MTT assay.
Data (mean ± SD) are representative of three independent experiments
(n=8 mice/group,
#p,0.05,
##p,0.01,
###p,0.001).
doi:10.1371/journal.pntd.0000797.g001
Figure 2. Antigen-specific antibodies were enhanced in
response to challenge T. cruzi infection in TcVac2-immunized
mice. Mice were vaccinated with TcVac2 and two-weeks after last
immunization, infected with T. cruzi (10,000 trypomastigotes / mouse).
Sera were collected at day 30 (A,C&E) and day 120 (B,D&F) post-
infection. The sera level of T. cruzi- and antigen-specific IgG (A&B),
IgG2b (C&D) and IgG1 (E&F) antibodies were measured by an ELISA
(n=8 mice/group,
#p,0.05,
##p,0.01,
###p,0.001). Abbreviations
are as in Figure 1.
doi:10.1371/journal.pntd.0000797.g002
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+ and CD8
+ T cells in acutely-infected mice
given vector alone, cytokines only, and TcVac2 vaccine were
17.8±1.4, 21.9±2.32, and 20.8±1.7; and 47.8±3.5, 42.3±3.7,
and 65.5±4.2, respectively (Fig. 4A). Together these data showed
that immunization with TcVac2 led to induction of a strong CD8
+
T cell and type 1 biased cytokine response to acute infection by T.
cruzi. In absence of vaccine-mediated polarization, mice elicited a
mixed type 1/type 2 cytokine response against T. cruzi infection.
In chronic phase (120 dpi), all infected mice, irrespective of
vaccination status, exhibited an overall decline in the extent of
lymphocyte activation and proliferation (Fig. 3F) as compared to
what was noted in acute stage (Fig. 3A). Yet, vaccinated/
chronically-infected mice exhibited a switch to CD4
+ T cells and
type 2 cytokines. This was evident by the fact that as compared to
vaccinated/acutely-infected mice, spleen cells of vaccinated/
chronic mice consisted a significantly higher number of CD4
+
(18.8%) than CD8
+ (10.5%) T cells (Fig. 4B) that produced higher
levels of IL-4 (Fig. 3I) and IL-10 (Fig. 3J) cytokines, and decreased
levels of IFN-c (Fig. 3G) and TNF-a (Fig. 3H) cytokines (IFN-
c+TNF-a,IL-4+IL-10). This polarization of cytokine response
(type 2.type1) in vaccinated/chronically infected mice was
evident when splenocytes were stimulated with Tc-lysate or
TcG1, TcG2 and TcG4 antigens (Fig. 3G–J). In comparison,
mice injected with vector alone or cytokines only maintained a
pro-inflammatory milieu during chronic phase as was evidenced
by higher mean percentage of CD8
+ (22.1 and 15.6%,
respectively) than CD4
+ (15.5and 11.5%, respectively) T cells.
Further, chronically infected mice injected with vector alone or
cytokines only exhibited higher levels of TcTL-stimulated splenic
release of IFN-c (435±22.8 and 520±32.5 pg/ml, respectively,
Fig. 3G) and TNF-a (325±25 and 365±34.2 pg/ml, respectively,
Fig. 3H) cytokines; and low-to-none IL-4 (Fig. 3I) and IL-10
(Fig. 3J) cytokines. These data suggested that mice vaccinated with
TcVac2 were equipped to control the chronic activation of CD8
+
T cell proliferation and proinflammatory cytokine (IFN-c and
TNF-a) production that are considered pathological in Chagas
disease.
Histological analysis revealed extensive infiltration of inflam-
matory cells in the heart and skeletal muscle of all acutely-infected
mice (Fig. 5A). In agreement with enhanced activation of B and T
cell responses, the extent of inflammatory infiltrate in heart tissue
and skeletal muscle of vaccinated/acutely-infected mice (histolog-
ical score 2–4, Fig. 5Ae-f) was significantly higher than that
detected in acutely-infected mice injected with vector or cytokines
only (histological score 1–3) (Fig. 5Aa–d). Accordingly, tissue
parasite foci were remarkably reduced (0–2 per microscopic field,
mf) in TcVac2-vaccinated mice harvested at day 30 pi (Fig. 5Ae-f).
In comparison, mice injected with vector only (2–10 parasite
nests/mf, Fig. 5Aa-b) or cytokine adjuvants (1–5 parasite nests/mf,
Fig. 5Ac-d) failed to control acute tissue parasite burden. The
decline in tissue parasite burden in vaccinated/acutely-infected
mice was validated by a semi-quantitative PCR (Fig. 5B) and real
time PCR (Fig. 5C). Our data demonstrated a 89–97% reduction
in amplification of Tc18SrDNA sequence in heart (91.6%), skeletal
muscle (89.3%), spleen (96.8%), liver (91%) and kidney (94%) of
vaccinated/acutely-infected mice when compared to that detected
in infected mice that were injected with vector or cytokines only
(Fig. 5B-5C, p,0.001).
At the chronic stage, the inflammatory infiltrate (Fig. 6Ae-f) and
tissue fibrosis (Fig. 6Be-f) were particularly absent in heart tissue
and skeletal muscle of TcVac2-vaccinated mice (histological score
0–1). Real time PCR amplification of parasite-specific
Tc18SrDNA sequence (for 50 cycles) detected no signal in the
heart, skeletal muscle, spleen, and liver tissue vaccinated/chronic
mice and Tc18S signal in kidney of vaccinated/chronic mice was
reduced by .95% as compared to that noted in non-vaccinated/
chronic mice (Fig. 6C). In comparison, extensive-to-moderate
Figure 3. TcVac2-immunized mice exhibited significant in-
crease in lymphocyte proliferation and type 1 cytokine
production in response to acute T. cruzi infection. Spleen cells
from mice sacrificed at day 30 (A–E) and 120 (F–J) pi were in vitro
stimulated with TcTL or recombinant antigens for 48 h. The extent of
lymphocyte proliferation was determined by an MTT assay (A&F). The
IFN-c (B&G), TNF-a (C&H), IL-4 (D&I), and IL-10 (E&J) levels in cell-free
supernatants were measured by an ELISA (n=8 mice/group,
#p,0.05,
##p,0.01,
###p,0.001).
doi:10.1371/journal.pntd.0000797.g003
Figure 4. CD8
+ T cell subset dominated in splenic T cell
population of TcVac2-vaccinated/acutely-infected mice. Mice
were vaccinated and challenged with T. cruzi, and harvested at day 30
(A) and 120 (B) post-infection, corresponding to acute infection phase
and chronic disease phase, respectively. Spleen cells were incubated for
30 min with FITC-conjugated anti-CD8 and PE-conjugated anti-CD4
antibodies and CD4
+ and CD8
+ T cell subsets monitored by flow
cytometry.
doi:10.1371/journal.pntd.0000797.g004
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fibrosis (histological score 2–4, Fig. 6Ba–d), and persistence of
parasites (Fig. 6C) dominated in heart and skeletal muscle of
chronic mice injected with vector or cytokines only. Noticeable
larger blue-stained areas, indicator of fibrosis, were evident in
Masson-trichrome-stained heart and skeletal muscle sections of
chronically-infected mice that were given vector or cytokines only
(Fig. 6Ba–d) as compared to TcVac2-immunized mice (Fig. 6Be-f).
These results demonstrated that TcVac2 was effective in arresting
the parasite persistence and associated inflammatory pathology
and tissue fibrosis in chronic Chagasic mice.
Discussion
The present study was performed to test the protective efficacy
of TcVac2 vaccine. The antigenic candidates included in TcVac2
were identified by computational analysis of T. cruzi sequence
database and selected because they were conserved among several
clinically relevant T. cruzi strains, and expressed as plasma surface
proteins in infective trypomastigote and intracellular amastigote
stages. The TcG1-, TcG2- and TcG4-specific antibodies exhibited
lytic activity against the infective trypomastigote form, suggesting
their potential utility as vaccine candidates [26]. We chose DNA-
prime/protein-boost approach to deliver the subunit vaccine
because DNA vaccines induce a T cell response that can be
strongly boosted by recombinant (or antigenically similar) proteins,
and DNA/protein vaccines have been shown to elicit stronger,
long-term immunity against intracellular pathogens than is noted
by DNA/DNA vaccines [31,32] [38]. We utilized IL-12 and GM-
CSF expression plasmids as adjuvants with DNA-prime dose as
these cytokines induce type 1 B and T cell responses [39,40], and
are shown to significantly enhance the protective immunity elicited
by the vaccine candidates in mice [5]. To the best of our
knowledge, no published report has tested the protective efficacy
against T. cruzi of a heterologous prime-boost vaccine constituted
of the selected candidates, and this is the first report demonstrating
vaccine’s efficacy in reducing the tissue parasite burden below
detection limits in chronic chagasic animals.
Mice immunized with TcVac2 elicited a strong parasite-specific
antibody response that was rapidly expanded after challenge T.
cruzi infection. The levels of IgG2b and IgG1 antibody isotypes
were significantly elevated in TcVac2-vaccinated mice, and the
antibody response was primarily of the Th1 type with IgG2b/
IgG1 ratios being .1 (Fig. 1). Others have shown that the lytic
IgG1 and IgG2 antibodies are involved in parasite clearance
[41,42]. For example, IgG2a elicited by immunization with
kinetoplastid membrane protein-11-encoding plasmid controlled
T. cruzi infection in rodents [11], while IgG1 and IgG2b were
found to be predominant isotypes in mice immunized with
complement-regulatory protein and trans-sialidase antigens
[10,43]. Another study showed low-to-none IgG1 levels in
chagasic dogs exhibiting cardiomegaly and chronic pathology
[44]. Previously, we have shown that TcG1-, TcG2- and TcG4-
specific antibodies were lytic in nature and efficiently killed
trypomastigotes in a complement-dependent manner [26]. In this
study, TcVac2-vaccinated mice exhibited a better control of T.
cruzi infection than was observed in mice injected with vector alone
or cytokines only, and this protection was correlated with
persistence of a high ratio of IgG2b/IgG1 antibodies (Fig. 2).
The tissue parasite foci and parasite burden were significantly
reduced in TcVac2-immunized mice at the acute stage (Fig. 5C).
Importantly, parasites were undetectable by a sensitive real time
PCR approach in multiple organs (heart, skeletal muscle, liver,
spleen) and barely detectable in kidney of vaccinated mice at
chronic stage (Fig. 6C). We surmise that vaccination with TcVac2
resulted in a rapid expansion of antigen-specific Th1 antibody
response upon challenge infection that contributed to effective
control of acute parasite burden and led to undetectable parasite
persistence in chronic stage.
A collection of studies in knock-out mice or in rodents treated
with antibodies to deplete specific immune molecules have shown
that beside T. cruzi-specific lytic antibody response, an efficient
Figure 5. Enhanced infiltration of inflammatory infiltrate
contributed to control of acute tissue parasite burden in
TcVac2-immunized mice. Mice were vaccinated with TcVac2 or
given vector or cytokines (cyt) alone, and challenged with T. cruzi.( A)
Shown are H&E staining (blue-nuclear and pink-muscle/cytoplasm/
keratin) of heart tissue and skeletal muscle (Sk Ms) sections at day 30 pi
(magnification: 20X). Arrows mark parasite nests in panels b & d. (B&C)
Total DNA from Heart (Hrt), Skeletal Muscle (Sk Ms), Spleen (Spl), Liver
(Liv) and Kidney (Kid) was isolated and used as a template for the
amplification of T. cruzi 18SrDNA sequence by traditional PCR (B) or real
time PCR (C). Standard deviation was ,12% for the data presented in
the Figure 5C (
##p,0.01,
###p,0.001).
doi:10.1371/journal.pntd.0000797.g005
Figure 6. Chronic inflammatory infiltrate, tissue fibrosis and
parasite burden were arrested inTcVac2-immunized/infected
mice. Heart tissue and skeletal muscle were harvested at 120 dpi
(chronic phase) and subjected to H&E (A) or Masson’s Trichrome (B)
staining (magnification: 20X). The intense blue color (Fig. 6B) shows the
collagen deposition (fibrotic area). (C) Real time PCR amplification of T.
cruzi 18SrDNA (as in Fig. 5C).
doi:10.1371/journal.pntd.0000797.g006
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macrophages, Th1 helper cells, and cytotoxic T lymphocytes
(CTLs) (reviewed in [45]). IFN-c and TNF-a cytokines are
believed to be the key inducers of macrophage activation, and
nitric oxide (NO) production and oxidative burst are required for
parasite clearance in early stages of infection [46]. CD4
+ T cells
secreting type 1 cytokines and CD8
+ CTLs capable of killing the
infected cells have been implicated in control of intracellular T.
cruzi [47,48]. The role of Th1 cytokines in the immune control of
T. cruzi has been addressed by the studies demonstrating that over
production of type 2 cytokines or blockage of type 1 cytokine
production correlates with increased susceptibility to T. cruzi
infection [49–52]. In this study, analysis of splenocyte T cell
subsets, and cytokine production in TcVac2-vaccinated/infected
mice showed a polarized response with dominance of IFN-c,
TNF-a, and CD8
+ T cells in the acute phase, and IL-4, IL-10, and
CD4
+ T cells in the chronic phase (Figs. 3,4). Mice given vector
alone or cytokines only elicited mixed type 1/type 2 responses
inefficient at achieving parasite clearance (Figs. 3–5). We propose
that polarization of immune response in vaccinated mice was
beneficial as protective effect of CD8
+ T cells and type 1 cytokines
(IFN-c and TNF-a) was not suppressed by IL-4 and IL-10
cytokines leading to an effective control of acute infection (Fig. 5).
A switch to type 2 dominance in vaccinated/chronic mice likely
suppressed the infiltration of inflammatory infiltrate that otherwise
was exacerbated (Fig. 6) with sustained IFN-c production in non-
vaccinated/chronic mice. The efficacy of heterologous DNA-
prime/protein-boost TcVac2 against T. cruzi was highlighted by
the fact that DNA-prime/DNA-boost vaccines have not been very
successful in providing sterile immunity to T. cruzi [20].
The persistence of inflammatory responses associated with tissue
fibrosis and cell death are hallmarks of chronic Chagas disease. It
is suggested that CD8
+ T cells, the dominant resident immune
cells in the heart have a toxic effect on the host, as many of the
CD8
+ T cells express granzyme A that causes non-specific
bystander cell death and tissue necrosis [53]. Others have shown
that the frequency of T. cruzi-specific IFN-c
+ T cells correlate with
severity of chronic disease in chagasic humans and experimental
animals [54,55]. Circulating levels of IFN-c and its production by
PBMCs in vitro stimulated with T. cruzi antigens has been implied
as a biomarker in identifying asymptomatic, seropositive patients
at risk of developing symptomatic chronic cardiomyopathy [54].
In this study, it was particularly interesting to note that frequency
of activated CD8
+ T cells and IFN-c and TNF-a cytokine levels in
lymphoid of TcVac2-vaccinated/chronic mice were considerably
lower than that observed in unvaccinated/chronic mice (Figs. 3,
4). Further, heart and skeletal muscle of vaccinated mice exhibited
minimal-to-no infiltration of inflammatory infiltrate. Also parasite
18SrDNA-specific real time PCR signal was minimal or not
amplified in the tissues (heart, skeletal muscle, spleen liver and
kidney) during the chronic stage (Fig. 6). Based on these studies
and our data, we conclude that TcVac2 elicited effective immune
responses capable of controlling the acute parasite burden below a
threshold level, and subsequently, prevented the consistent
activation and infiltration of inflammatory cells in the heart that
otherwise occur due to parasite persistence and result in tissue
destruction during the chronic phase.
In summary, we have demonstrated that DNA-prime/protein-
boost TcVac2 vaccine provided resistance to T. cruzi infection.
Mice immunized with TcVac2 responded to T. cruzi infection with
a rapid and potent expansion of type 1 antibodies, CD8
+ T cells,
and proinflammatory cytokines that effectively controlled the
acute parasitemia and tissue parasite burden. Consequently,
evolution of chronic immunopathology and tissue damage, an
outcome of parasite persistence and consistent immune activation,
were absent in vaccinated mice.
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